Pyridine Phenyl Ophthalmic Formulation for Process Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ophthalmic formulations of pyridine phenyl compounds lack efficacy and safety data for treating ophthalmic diseases such as dry eye disease, allergic conjunctivitis, and other ocular conditions, and require a stable preparation process.
Innovation Solution
Development of an ophthalmic formulation containing pyridine phenyl compounds, solubilizing agents, pH modifiers, osmotic pressure regulators, antimicrobial preservatives, and antioxidants, with specific compound variations and concentrations, formulated through methods like rotary evaporation and freeze-drying.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pyridine phenyl compounds are administered as eye drops to treat dry eye disease, then the toxicity of aldehydes is reduced and inflammation is lowered, but the formulation stability and preparation process reliability are insufficient
Solution Approach 1:
The patent introduces cyclodextrin as an intermediary substance that forms inclusion complexes with pyridine phenyl compounds. This mediator enhances the solubility and stability of the active ingredient while maintaining its therapeutic efficacy against aldehyde toxicity and inflammation in dry eye disease treatment
Solution Approach 2:
The formulation employs composite material strategies by combining pyridine phenyl compounds with cyclodextrin derivatives and other excipients to create a stable ophthalmic preparation. This composite approach ensures both therapeutic effectiveness and formulation stability for clinical use
2Object-affected harmful factors
If pyridine phenyl compounds are used to complex with endogenous aldehydes, then the toxicity is reduced, but the preparation process complexity increases
Solution Approach 1:
The patent utilizes parameter changes in the chemical structure of pyridine phenyl compounds to optimize their complexation ability with endogenous aldehydes. By modifying molecular parameters such as substitution patterns and functional groups, the formulation achieves effective aldehyde binding while simplifying the overall preparation process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a safe and effective treatment for ophthalmic diseases with stable quality, improving tear secretion and reducing corneal damage, while minimizing adverse reactions.
Implementation Method 1
through complexation reactions with endogenous aldehydes, therefore the toxicity of aldehydes is reduced, inflammation is lowered
Implementation Method 2
formulated through methods like rotary evaporation and freeze-drying
Implementation Method 3
formulated through methods like rotary evaporation and freeze-drying
Data Source
Figure 1~2
Figure 3~5
Figure 6~7
AI summary
The present invention belongs to the field of pharmaceutical preparations and discloses an ophthalmic formulation containing pyridine phenyl compounds, its preparation method, and application. The ophthalmic formulation includes an active ingredient pyridine phenyl compounds and excipient. The active ingredient pyridine phenyl compounds include compounds of formula (II), their isomers, or their pharmaceutically acceptable salts. It can be used for dry eye disease, allergic conjunctivitis, macular degeneration, cataracts, keratoconus, bullous keratopathy, Fuchs endothelial corneal dystrophy, ocular cicatricial pemphigoid, meibomian gland dysfunction, uveitis, scleritis, Stevens-Johnson syndrome, ocular rosacea, Sjögren syndrome.